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Abstract 
 
Objectives 
To evaluate magnetic resonance (MR)-derived whole-tumor histogram analysis 
parameters in predicting aggressiveness of pancreatic ductal adenocarcinomas 
(PDACs) and neuroendocrine neoplasms (panNENs). 
 
Methods 
Pre-operative MR of 169 consecutive patients with PDAC or panNEN were 
retrospectively analyzed. T1-/T2-weighted images and apparent diffusion 
coefficient (ADC) maps were analyzed. Histogram-derived parameters were 
compared to several pathological features (grade, vascular infiltration, nodal and 
hepatic metastases) using Mann-Whitney U test. Diagnostic accuracy was assessed 
by receiver operating characteristic area under curve (ROC-AUC) analysis; 
sensitivity and specificity were assessed for each histogram parameter. 
 
Results 
No significant differences were found among histogram parameters for prediction 
of PDACs grade. ADCentropy was significantly higher in G2-3 panNENs with ROC-
AUC 0.757; sensitivity was 83.3%. ADCentropy was significantly higher in PDACs 
with vascular involvement (p=.022; AUC=.641), with specificity of 92.2%. 
ADCskewness was significantly higher in PDACs with nodal metastases (p=.027; 
AUC=.642), with 72% specificity. ADCkurtosis was higher in panNENs with vascular 
involvement, nodal and hepatic metastases (p= .008, .021, and .008; ROC-AUC= 
0.820, 0.709, and 0.820); sensitivity and specificity were: 85.7/74.3%; 36.8/96.5%; 
and 100/62.8%. No significant differences between groups were found for other 
histogram-derived parameters (p >.05). 
 
Conclusions 
Whole-tumors histogram analysis of ADC values is a valuable tool for predicting 
aggressiveness of PDACs and panNENs. Our results indicate that histogram 
metrics related to intra-tumor heterogeneity, as ADCentropy, ADCkurtosis and 
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ADCskewness are the most accurate parameters for the identification of PDACs and 
panNENs with higher biological aggressiveness. Further and larger studies are 
needed to incorporate the results of the histogram analysis within decision support 
models and to mine these data to detect possible correlations with genomic patterns. 
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1. Introduction 
 
a) Epidemiology, pathology and molecular/genomic landscape of solid pancreatic 
tumors 
Pancreatic tumors arise from both the exocrine and endocrine parenchyma of the 
gland; however, about 95% occur within the exocrine portion and may arise from 
ductal epithelium, acinar cells, or connective tissue, and only 2% of these exocrine 
tumors are benign. The most common solid pancreatic malignancy is ductal 
adenocarcinoma (PDAC), accounting for about 80% of all pancreatic cancers. 
Pancreatic adenocarcinoma represents the fourth cause of cancer death in Europe 
in both genders, after lung, colorectal, and prostate cancers in men, and after breast, 
colorectal and lung cancers in women [1]. The mortality rate of PDAC in Europe 
has increased by around 20% over the last 10 years [1]; incidence and mortality 
rates are very similar, due to the dismal prognosis of this tumor, with a life 
expectancy of about 5% at 5 years, that has not significantly improved over the last 
20 years [1]. The mean age at diagnosis is 71 and 75 years in men and women, 
respectively. The vast majority (>80%) of PDACs are caused by sporadic occurring 
genetic alterations. The most relevant acquired risk factors for PDAC are cigarette 
smoking (overall relative risk, ORR, 1.74) and obesity (body mass index (BMI) > 
30 kb/m2 ), which is associated with an increase by 20-40% of death from 
pancreatic cancer. Other risk factors include diabetes (ORR for type 1 and type 2 
diabetes: 2.0 and 1.8, respectively) and chronic pancreatitis, that most commonly 
depends, in Europe, by alcohol consumption, which is itself considered a risk factor 
for pancreatic cancer [2]. Additionally, Helicobacter pylori, hepatitis B and human 
immunodeficiency virus infection have been associated with an increase in relative 
risk of pancreatic cancer [2]; between dietary factors, regardless of their role in 
causing obesity, butter, saturated fat, red meat, and processed foods are considered 
risk factors for pancreatic cancer, whereas a high fruit and folate intake may have a 
protective role [3]. Finally, many chemical substances (such as chlorobenzoil, 
chlorinated hydrocarbon, nickel and nickel compounds, chromium compounds, 
silica dust), have been reported to increase the relative risk of developing pancreatic 
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cancer [4]. About 5-10% of PDACs are caused by inherited germline mutations [2], 
and are defined familial PDACs; this condition should be suspected and 
investigated when at least two first-degree relatives have been diagnosed with 
pancreatic cancer. Mutation in BRCA2 is the most common known inherited 
disorder in familial PDAC; germline mutation in other genes, such as p16, ATM, 
STK11, PRSS1/PRSS2, SPINK1, PALB2, and DNA mismatch repair genes, are 
associated with pancreatic cancer risk increase [2]. About two thirds of PDACs (60-
70%) arise in the head of the pancreas, 20-25% in the body and in the tail, and 10-
20% diffusely involve the pancreas. Early symptoms are strictly connected with the 
tumor position within the gland: pancreatic head tumors often present with “mass 
effect” symptoms, such as jaundice or upper gastroduodenal obstruction due to 
compression/invasion of the common bile and/or the pancreatic duct or the 
duodenum; body-tail tumors are generally associated with non-specific symptoms, 
such as abdominal or back pain, weight loss, steatorrhea, and new-onset diabetes 
[5]. Surgical resection is the only potentially curative treatment, leading to a post-
operative 5-year survival rate of about 20%. Unfortunately, only 15-20% of patients 
present with resectable disease at diagnosis, whereas most patients present with 
PDAC in an advanced stage, that ranges from inoperable, locally advanced to 
metastatic disease. The best treatment strategy in each patient needs to be discussed 
by a multidisciplinary team in order to define treatment goals and possible ways to 
achieve them. Locally advanced tumors, defined as neoplasms with no evidence of 
distant metastases but that are not resectable nor borderline resectable, have an 
intermediate prognosis: median overall survival range from 9-12 months in 
untreated patients to 16 months in patients treated with active chemotherapy [6]. 
Chemoradiation is another option in this subgroup; however, it remains unclear 
whether the addiction of radiotherapy leads to superior survival compared to 
chemotherapy alone [6-11]. In the metastatic setting, the main treatment goal is 
palliation. For patients with good performance status (ECOG 0-1), adequate biliary 
drainage and liver function, lengthening of survival is another possible purpose, 
that may be pursued through the use of systemic therapy [12]; however, even with 
the use of polychemotherapy, the prognosis remains poor, with a median OS of 7 
to 11 months according to the treatment received [13,14]. Macroscopically, PDAC 
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usually presents as solid, firm mass, with ill-defined margins. Microscopically, 
PDACs are characterized by an intense stromal reaction surrounding tumor cells 
[15]; these may vary from well-differentiated, duct-forming tumor cells, to poorly 
differentiated cells, with epithelial differentiation demonstrable only on 
immunolabelling. Morphological variants of PDAC include colloid carcinoma, 
medullary carcinoma, acinar cell pancreatic cancer (with slightly better prognosis), 
adenosquamous carcinoma and undifferentiated carcinomas with osteoclast-like 
giant cells, the last two associated with a poorer prognosis [16]. Most PDACs 
originate from a precursor lesion called pancreatic intraepithelial neoplasia 
(PanIN), a microscopic (<5mm) mucinous-papillary lesion that evolve to invasive 
carcinoma through an adenoma-carcinoma sequence [17]. Other potential precursor 
lesions are IPMNs and mucinous cystic neoplasms, that can also lead to invasive 
PDAC by stepwise gene alterations. Multiple genetic alterations are commonly 
found in PDACs: mutational activation of oncogenes (predominantly KRAS, found 
in >90% of PDACs), inactivation of tumor suppressor genes (such as TP53, 
p16/CDKN2A, and SMAD4), and inactivation of DNA damage repair genes (such 
as hMLH1 and MSH2) [18]. A recent whole-genome sequencing and copy number 
variation analysis [19] found chromosomal rearrangements as the most common 
event, causing disruption of genes involved in pancreatic cancer initiation and 
progression (TP53, SMAD4, CDKN2A, ARID1A, ROBO2, KDM6A and PREX2). 
According to the patterns of structural variation in chromosomes, a classification 
of PDACs into four subtypes with potential clinical utility has been proposed: 
stable, locally rearranged, scattered, and unstable subtype [20]. 
Pancreatic neuroendocrine neoplasms (panNENs) are the second most frequent 
tumor type arising in the pancreas. Neuroendocrine neoplasms (NENs) are 
classified according to their site of origin, their proliferation index and their 
functional status. The main division depending on NENs proliferation index 
(ki67%) is between well and poorly differentiated tumors, with the former being 
grouped together as grade 1 (ki67 < 3%) and grade 2 (ki67 2-20%) neuroendocrine 
tumor (NETs) and the latter being described as grade 3 (ki67 > 20%) 
neuroendocrine carcinomas (NECs) [20]. Recently, however, it has been pointed 
out that that within these groups there is significant heterogeneity of behavior, and 
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further subdivisions (i.e. highly proliferative but better differentiated tumors with a 
Ki-67 of <50% and truly poorly differentiated tumors with Ki-67 of >50%) may be 
useful to achieve better prognostic and predictive results [21]. According to the 
functional status, NENs are described as functional when signs and symptoms 
consistent with excess hormone secretion are found, regardless of hormone staining 
on immunohistochemical testing [22]. Insulinomas are the most common subtype of 
functioning PanNET, with an annual incidence of 0.5/100000 [23]. 
I n s u l i n o m a s  are usually smaller than 2 cm, solitary, hypervascular, and tend 
to exhibit very low malignant potential. The clinical presentation of insulinomas 
is characterized by the classic “Whipple triad,” consisting of symptomatic 
hypoglycemia, low blood glucose levels, and relief of symptoms after glucose 
administration [24]. Gastrinomas are typically malignant tumors and cause the 
Zollinger-Ellison syndrome, which is characterized by peptic ulceration, 
heartburn, and diarrhea [25]. Vasoactive intestinal polypeptide (VIP) stimulates 
intestinal secretion and inhibits electrolyte and water absorption: consequently, 
VIPomas are associated with profuse, watery diarrhea and electrolyte abnormalities, 
including hypokalemia (Verner-Morrison syndrome) [26]. The clinical 
manifestations of glucagonomas include hyperglycemia, weight loss, venous 
thromboses, glossitis, and an unusual rash called necrolytic migratory erythema, 
likely caused by amino-acid or zinc deficiencies [27] .  Somatostatinomas are 
characterized by the effects of hypersecretion of somatostatin and usually present 
with steatorrhea, achlorhydria, diabetes mellitus, and cholelithiasis. Rarely, pNETs 
may secrete adrenocorticotropic hormone, parathyroid hormone-related peptide, 
growth hormone-releasing hormone, cholecystokinin, and serotonin, giving rise to 
the respective clinical syndromes [28]. However, most (60-90% in recent series) 
PanNENs are silent hormonally, therefore defined as “non-functioning” (NF Pan-
NENs) [29]; additionally, most PanNENs are well to moderately differentiated (G1-
2 NETs) rather than NECs, with a relatively indolent behavior [30,31]. The crude 
annual incidence of NF PanNENs is 1.8 in females and 2.6 in males; their relatively 
good prognosis lead to a higher prevalence [30,32], although NF PanNENs seem 
to have worse prognosis compared with functioning tumors, probably as result of 
late diagnosis. In fact, NF-PanNENs usually become clinically apparent when they 
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reach a size that causes compression or invasion of adjacent organs, or when they 
metastasize: the most common presenting symptoms are abdominal pain (35–78%), 
weight loss (20–35%), anorexia and nausea (45%), whereas less frequent signs are 
intra-abdominal hemorrhage (4–20%), jaundice (17–50%) or a palpable mass (7–
40%) [33-37]. According to SEER data [32], localized, regional, and distant stages 
corresponded to 14, 23, and 54% of cases, respectively. Median overall survival for 
patients with NF PanNENs ranges between 23 months of patients with metastatic 
disease to 70 and 124 of those with locoregional and localized disease, respectively 
[32]. Beyond stage, tumor grade is the main prognostic factor [38-40]: patients with 
G2 and G3 neoplasms have a respective 2- and 10-fold higher risk of death [41]. 
The only known risk factor for PanNENs development is the presence of specific 
hereditary syndromes, such as Multiple Endocrine Neoplasia Type 1 (MEN-1), Von 
Hippel-Lindau Disease (VHL) and Tuberous Sclerosis (TS) [29]. Although only a 
small number of patients with PanNENs have MEN-1 syndrome, these neoplasms 
occur in the 19% of patients diagnosed with MEN1 with an incidence of 3, 34 and 
53% of patients at age 20, 50, and 80 years [42]. The incidence of PanNENs in 
VHL syndrome, instead, ranges from 11 to 17% [43,44]; NENs in VHL have a good 
prognosis although a small fraction of patients have an aggressive disease. 
Microscopically, most NF-NENs are well-differentiated tumors consisting of small, 
monomorphic cells arranged in islets or trabeculae with a “salt-and-pepper” 
chromatin pattern. Conversely, poorly differentiated tumors are often characterized 
as sheets of pleomorphic cells with extensive necrosis [22]. Immunohistochemical 
markers of neuroendocrine differentiation include synaptophysin, chromogranin A 
(CgA), neuron-specific enolase (NSE), and cluster of differentiation 56 (CD56) 
(neural cell adhesion molecule). [22]. As NETs arising in other organs, PanNETs 
are characterized by high-density expression of somatostatin receptors (SSTRs) 
[45]; well-differentiated NETs express SSTRs at an increased frequency and higher 
levels compared with poorly differentiated NECs. Aberrant activation of signaling 
by the mammalian target of rapamycin (mTOR) is a hallmark of NETs, regardless 
of primary site; mTOR modulates cell survival and proliferation, angiogenesis, and 
metabolism, and mutations in the mTOR pathway are observed in approximately 
15% of pNETs [46,47]. NETs are among the most vascularized cancers: tumor 
11 
 
 
 
neoangiogenesis has been identified as a key event in NET progression, associated 
with overexpression of proangiogenic factors, including vascular endothelial 
growth factor (VEGF), fibroblast growth factor, platelet-derived growth factor 
(PDGF), and their receptors [48,49]. From a genomic point of view, in PanNETs, 
losses of genetic material have been described more often than chromosomal gains 
[50] a whole-genome sequencing study of 102 primary pNETs identified 4 
signaling pathways commonly dysregulated in such tumors: 1) DNA damage 
repair; 2) chromatin remodeling; 3) telomere maintenance; and 4) mTOR 
activation. A higher than expected proportion of germline mutations has been 
demonstrated in clinically sporadic pNETs with mutations of the genes mutY 
homolog (MUTYH), checkpoint kinase 2 (CHEK2), and BRCA2 recurring in 11% 
of patients [47]. Surgery represents the treatment of choice for localized PanNENs 
since it is associated with significant benefits in terms of survival [51]. 
Nevertheless, the improvement of cross-sectional imaging techniques significantly 
increased the detection of small NF-NET and it is now debated if all the small (< 2 
cm) and asymptomatic lesions should be routinely resected [52], since most of 
neoplasms < or = 2 cm are likely benign or intermediate-risk lesions and only 6% 
of NF pancreatic NETs < or = 2 cm are malignant when incidentally discovered 
[53]. The choice of the appropriate management of these small tumors should be 
well balanced with the short- and long-term sequelae of pancreatic resection 
procedures, and a ‘watchful-waiting’ strategy could be a reasonable first approach. 
Many therapeutic options are available for advanced PanNENs, and again, the 
optimal treatment strategy (and the optimal sequence of therapies) should be 
discussed by an expert multidisciplinary board, taking into consideration the final 
treatment goal. Of course, in patients with functioning tumors, palliation of 
hormonal symptoms is the priority. Somatostatin is a hypothalamic hormone with 
wide exocrine, endocrine, paracrine, and autocrine inhibitory effects. Synthetic 
somatostatin analogues (SSAs) octreotide and lanreotide bind with high affinity to 
SSTR2 and with moderate affinity to SSTR5, inducing rapid palliation of symptoms 
in around 90% of patients with carcinoid syndrome, VIPoma and glucagonoma 
[45,54]. SSAs also are effective in palliating symptoms in patients with gastrinoma, 
although high-dose proton pump inhibitors may be even more essential in 
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controlling the gastric acid overproduction. Patients with advanced insulinoma 
respond poorly to SSAs, likely because of low expression of SSTR2 by these 
tumors. Besides symptoms management, inhibition of tumor growth is another, 
fundamental treatment goal. SSAs have a role also in this setting, leading to a 
significant improvement in progression free survival (PFS) and overall survival  
(OS) in patients with well differentiated panNETs [55,56]; other potential therapies 
include radiolabeled somatostatin analogs (PRRT) [22], targeted therapies such as 
everolimus [57] and sunitinib [58], but also chemotherapy and locoregional 
treatments (i.e. transarterial embolization, TAE, or transarterial 
chemoembolization, TACE, cytoreductive surgery and liver transplant in selected 
cases) [22]. Data to guide the best selection of treatment after progression of disease 
on SSAs are scarce; randomized studies comparing active drugs are needed to 
provide additional data on the appropriate sequencing of treatments.  
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b) Imaging 
 
Pancreatic ductal adenocarcinoma usually presents as a solid mass with infiltrative 
and ill-defined margins, causing ductal obstruction with secondary dilation of the 
main pancreatic duct and -when located in the pancreatic head- also of the common 
bile duct (“double-duct sign”). Pancreatic carcinoma is usually hypoechoic on B-
mode ultrasound (US), hypo- or isodense on unenhanced computed tomography 
(CT), hypointense on T1-weighted images and with a variable appearance on T2-
weighted images of magnetic resonance (MR) imaging. On contrast-enhanced 
examinations, PDAC is characterized by a hypoenhancing appearance, especially 
during the arterial phase. On delayed phase of CT and MR examinations, PDAC 
may present a mild pooling of contrast media with a slightly hyperdense/-intense 
appearance, owing to contrast medium retention within desmoplastic fibrosis [59]. 
Neuroendocrine neoplasms have a wide range of possible imaging appearances. 
They usually present as solid masses with well-defined margins, variably associated 
with dilation of the main pancreatic duct and the common bile duct. Larger tumors 
frequently present an inhomogeneous appearance, with coexistence of viable tumor 
tissue, necrosis, calcifications, etc. Neuroendocrine tumors are usually hypoechoic 
on B-mode US, hypo- or isodense on unenhanced CT, hypointense on T1-weighted 
images and hyperintense on T2-weighted images of MR imaging. On contrast-
enhanced examinations, panNENs are typically hyperenhancing during the arterial 
phase; contrast medium retention over time may be present [60]. 
Diffusion-weighted imaging (DWI) is a relatively recent technical improvement of 
MR imaging which has an established role in the evaluation of pancreatic diseases. 
DW sequence can evaluate the diffusion of water molecules (the so-called 
Brownian motions) within biological tissues: all factors that narrow the 
extracellular compartment or modify water exchanges through cell membranes lead 
to an impairment of the diffusion of water molecules, that can be identified by DWI. 
Tissues with restriction of water diffusion present high signal intensity on DW 
images and low signal intensity on the apparent diffusion coefficient (ADC) map; 
diffusion restriction can be also quantified through the calculation of the ADC value 
within specific regions of interest (ROIs). 
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DWI appears to be a promising adjunct for the identification of solid pancreatic 
tumors and for the diagnosis of liver metastases. For example, a previous study [61] 
reported that b800 DWI images provides higher conspicuity of 
panNENs compared to conventional MR sequences, thus leading to higher 
detection rates (93.3 vs. 71%): a probable explanation is that DW images have a 
high contrast resolution thanks to the decay of the MR signal of the pancreas and 
the peripancreatic structures on high b-value images, while pancreatic tumors, 
including panNENs, usually present diffusion restriction, with preservation of the 
MR signal, owing to the coexistence of dense cellularity, fibrosis and structural 
rearrangement that lead to an impaired diffusion of water molecules. As a 
consequence, both visual analysis and quantification of the conspicuity on high-b-
value DW images will provide a better identification of these tumors. Nevertheless, 
previous studies have reported controversial results regarding the performance of 
DWI in terms of the detection of panNENs: a small study conducted by Bakir et al 
[62], comprising 12 panNENs, reported that DWI does not appear to add useful 
additional information to a routine MR imaging protocol in the evaluation of 
panNENs, as the detection rates with DWI and conventional sequences were similar 
(100 and 91.7%, respectively); nevertheless, the authors of this study concluded 
that in patients with clinical suspicion for panNENs with negative or doubtful 
imaging modality outcomes, DWI may provide ancillary findings to the routine 
abdominal MR examination. Some other authors suggested that DWI findings 
might increase the diagnostic accuracy of conventional MR sequences. Brenner et 
al [63] reported that the addition of postprocessed fusion images of T2 and b1000 
DW images when reading MR studies of panNENs significantly increased the 
agreement on and confidence in the diagnosis of this neoplasia. A study by Schmid-
Tannwald et al [64] reported that the detection rate with conventional MR 
sequences was significantly improved by the addition of DW images, increasing it 
from 24.8–39.1 to 60.9–65.2%. Previous studies reported that DWI may provide 
ancillary findings that might be useful for prognostication. Prognosis in patients 
with PDAC is partially influenced by the histopathologic grade; ideally, well-
differentiated PDACs should present higher ADC values as compared to low-grade 
tumors, but some authors reported opposite findings as well as non-significant 
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results. It is reasonable to believe that the main contribution to the restriction of 
water diffusion in PDACs is provided by fibrosis, which is the predominant part of 
this tumor, while the contribution of the cells - even if less differentiated - and the 
perfusion effect provided by blood vessels should be minimal. Wang et al [65] 
reported that PDACs containing dense fibrosis had significantly lower ADC values 
compared to those characterized by abundant neoplastic tubular structures; 
moreover, well/moderately differentiated PDACs with dense fibrosis showed also 
significantly lower ADC values than those with loose fibrosis. Muraoka et al [66] 
reported similar findings: the mean ADC value was significantly higher in PDACs 
with loose fibrosis (1.88± 0.39 ×10-3 mm2/s) than in those with dense fibrosis (1.01 
± 0.29 ×10-3 mm2/s, p<.05). On the other hand, Rosenkrantz et al [67] did not report 
significant difference in mean ADC between poorly and well/moderately 
differentiated tumors. Moreover, Legrand et al [68] reported that mean ADC values 
did not differ significantly between tumors having < 50% of fibrotic stroma and 
those having >50% of fibrotic stroma (p=.94), or between tumors containing dense 
fibrosis and those containing loose fibrosis (p=.81). Some authors have proposed a 
more practical role for DWI, testing correlations with clinical features or outcomes 
(e.g., tumor stage, aggressiveness, or survival) rather than the histopathologic 
grade. Hayano et al [69] reported a significant negative correlation between ADC 
and tumor size (r=-0.59, p=.004) and the number of metastatic lymph nodes (r=-
0.56, p=.007). Tumors with low ADC values had a significant higher tendency to 
show portal system and extra-pancreatic nerve plexus invasion (p=.04 and .01, 
respectively) than those with high ADC. On the contrary, Rosenkrantz et al [67] did 
not report significant difference in mean ADC between tumors with stage T3 vs 
stage T1/T2, or between tumors with and without metastatic peri-pancreatic lymph 
nodes. Fukukura et al [70] reported that the median ADC value of PDACs was not 
associated with significantly differences in survival. Several studies identified 
predictors of aggressiveness by comparing DW and pathological features of 
panNENs, which could be helpful in the prognostication of these tumors. For 
instance, Lotfalizadeh et al [71] and Guo et al [72] reported that the mean ADC 
value tends to decrease as tumor grade increases. Similar results were reported by 
another study [73], which also reported an inverse correlation between the mean 
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ADC and tumor stage. Basing on these results, ADC seems to be correlated with 
aggressiveness in panNENs. 
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c) Radiomics and radiogenomics 
 
The suffix -omics originated in molecular biology disciplines to describe the 
detailed characterization of biologic molecules such as DNA (genomics), RNA 
(transcriptomics), proteins (proteomics), and metabolites (metabolomics). Now, the 
term is also being used in other medical research fields that generate complex high-
dimensional data from single objects or samples. One desirable characteristic of -
omics data is that these data are mineable and, as such, can be used for exploration 
and hypothesis generation. The term radiomics describes the conversion of digital 
medical images into mineable high-dimensional data, and it is motivated by the 
concept that biomedical images contain information that reflects underlying 
pathophysiology and that these relationships can be revealed via quantitative image 
analyses. 
Radiomics is a process designed to extract a large number of quantitative features 
from digital images (density/intensity, shape, size/volume, texture, etc.) which offer 
information on tumor phenotype and microenvironment, place these data in 
databases, and subsequently mine the data for hypothesis generation and/or testing. 
The final objective of radiomics is to develop decision support tools; therefore, it 
involves combining radiomic data with other tumor and patient characteristics 
(aggressiveness, biological behavior, survival, etc.) to increase the power of the 
decision support models. Radiomics appears to offer a nearly limitless supply of 
imaging biomarkers that could potentially aid cancer detection, diagnosis, 
assessment of prognosis, prediction of response to treatment, and monitoring of 
disease status [74]. 
The mining of radiomic data to detect correlations with genomic patterns is known 
as radiogenomics, and it has elicited great interest in the research community. The 
value of radiogenomics stems from the fact that while virtually all patients with 
cancer undergo imaging at some point and often multiple times during their care, 
not all of them have their disease genomically profiled. Furthermore, when genomic 
profiling is performed, it is done one time at one location and is susceptible to 
sampling error. Thus, radiogenomics has two potential uses. First, a subset of the 
radiomic data can be used to suggest gene expression or mutation status that 
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potentially warrants further testing. This is important because the radiomic data are 
derived from the entire tumor rather than from just a sample. Thus, radiomics can 
provide important information regarding the sample genomics and can be used for 
cross-validation. Second, a subset of radiomic features is not significantly related 
to gene expression or mutational data and, hence, has the potential to provide 
additional, independent information. The combination of this subset of radiomic 
features with genomic data may increase diagnostic, prognostic, and predictive 
power. 
While radiomics primarily grew out of basic research, lately it has also elicited 
interest from those in clinical research, as well as those in daily clinical practice. 
For example, visualization of tumor heterogeneity may prove critical in the 
assessment of tumor aggressiveness and prognosis. For example, research has 
already shown the capacity of radiomics analyses to help distinguish prostate cancer 
from benign prostate tissue or add information about prostate cancer aggressiveness 
[75]. In the evaluation of lung cancer, radiomics has been shown to be a tool with 
which to assess patient prognosis [76]. Therefore, radiomics offers important 
advantages for assessment of tumor biology. It is now appreciated that most 
clinically relevant solid tumors are highly heterogeneous at the phenotypic, 
physiologic, and genomic levels [77-79] and that they continue to evolve over time. 
Genomic heterogeneity within tumors and across metastatic tumor sites in the same 
patient is the major cause of treatment failure and emergence of therapy resistance 
[80]. Thus, precision medicine requires not only in vitro biomarkers and companion 
diagnostics but also spatially and temporally resolved in vivo biomarkers of tumor 
biology. A central hypothesis driving radiomics research is that radiomics has the 
potential to enable quantitative measurement of intra- and intertumoral 
heterogeneity. Moreover, radiomics offers the possibility of longitudinal use in 
treatment monitoring and optimization or in active surveillance. 
The tools developed for radiomics can help in daily clinical work, and radiologists 
can play a pivotal role in continuously building the databases that are to be used for 
future decision support. Radiomics analyses epitomize the pursuit of precision 
medicine, in which molecular and other biomarkers are used to predict the right 
treatment for the right patient at the right time. The availability of robust and 
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validated biomarkers is essential to move precision medicine forward. A major 
strength of a radiomics approach for cancer is that digital radiologic images are 
obtained for almost every patient with cancer, and all of these images are potential 
sources for radiomics databases. In the future, it is possible that image interpretation 
for all these studies will be augmented by using radiomics, building an 
unprecedented source of big data that will expand the potential for discovering 
helpful correlations. While radiomics will allow better characterization of patients 
and their diseases through new applications of genomics and improved methods of 
phenotyping, it will also add to the challenges of data management, as we will 
discuss later in this article.  
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d) Imaging evaluation of tumor heterogeneity 
 
Investigating tumor heterogeneity is a key point in cancer research. Tumors are 
highly heterogeneous on the histopathological level, with spatial variation in 
cellularity, angiogenesis, extracellular matrix, and necrosis. Moreover, 
heterogeneity in tumors already exists at the cell level and is highly influenced by 
the genetic background of tumor’s cells as well as the environment where they 
develop [81]. 
Intra-tumor heterogeneity has implications on clinical outcome as well as on the 
development of adequate therapies, as it may limit an adequate diagnosis and is 
involved in tumor resistance to chemo- and radiotherapy. The identification of 
multiple cellular clones within tumors orientated newer therapies towards more 
personalized treatments; therefore, a better and more systematic appreciation of 
intra- and inter-tumor heterogeneity is crucial for drug development as well as for 
the accurate assessment of response to treatment. Thus, a better characterization of 
cancer biology with non-invasive methods in conjunction with an enhanced 
knowledge of the molecular, metabolic and genomic profile of tumors might help 
the development of new clinically relevant biomarkers. 
It is difficult to assess tumor heterogeneity with invasive diagnostic methods as 
fine-needle aspiration or biopsy, as these do not represent the full extent of 
phenotypic or genetic variation within a tumor. On the contrary, imaging 
techniques, including MR imaging, CT and positron emission tomography (PET) 
are the ideal tools to analyze tumor heterogeneity in a non-invasive manner. The 
development of imaging techniques and dedicated software for quantitative and 
qualitative analysis have tremendously improved the evaluation of tumor 
heterogeneity over the last years. The strength of MR imaging compared with other 
imaging modalities resides in its potential to provide a vast array of different image 
contrasts, including T1, T2, contrast enhancement and perfusion, and DWI at a high 
spatial resolution and in a three-dimensional manner, providing unique insight into 
tumor heterogeneity. 
Independently from the technique, there are several modalities for assessing tumor 
heterogeneity with cross-sectional imaging. Among them, histogram analysis is 
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more and more used. This methodology proved its usefulness for investigating the 
distributions of various parameters such as permeability in dynamic contrast-
enhanced MR [82,83] and ADC in DW-MR imaging [84]. 
The histogram of an image is a function showing -for each intensity level- the 
number of pixels in the whole image having the same intensity. Histogram analysis 
uses descriptive parameters to report several quantitative factors, as mean, standard 
deviation, mode, maximum and minimum, kurtosis, skewness, and percentiles, 
entropy, etc. Mean and standard deviation represent average and dispersion of the 
histogram, respectively; kurtosis reflects the peakedness of the distribution and is a 
measure of the shape of the probability distribution; skewness is a measure of 
asymmetry of the probability distribution; entropy is a statistical measure of the 
irregularities in a histogram, allowing the description of the variation of a parameter 
of interest’s distribution; finally, a percentile represents the value below which a 
percentage of observations is calculated. The meaning of these metrics in cancer 
studies is still under investigation; nevertheless, many studies agreed that 
histogram-derived parameters can be significant predictors of prognosis and 
response to treatment in various types of cancers. Most clinical studies using MR 
imaging histogram analysis were performed in the brain, but histogram analysis is 
increasingly used for extra-cranial oncologic imaging. Basing on previous reports, 
kurtosis, skewness and percentiles seem to be promising parameters for 
differentiating between different types of gliomas [85], between pseudo- and early 
progression in glioblastomas [86,87] and between cancer subtypes [88]. Percentiles, 
kurtosis and skewness of ADC distributions allowed grading of endometrial cancer 
[89]. Finally, histogram analysis of MR images showed its added value as predictor 
of response to treatment in various cancers [83,90-92]. 
Histogram analysis of ADC is particularly useful to evaluate tumor heterogeneity 
as it analyzes different microenvironments that may be masked by evaluating mean 
ADC values, as happens during the conventional analysis of DW images. 
Biomarkers estimated from DWI have been related to cancer aggressiveness and 
response to therapy. Nowadays, most studies report histogram investigations of 
ADC in tumors. For example, ADC histograms were found to be able to 
differentiate astrocytomas from oligodendrogliomas by statistical comparisons of 
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mean, mode, peak height, percentiles and skewness [94]; another study found that 
the 75th percentile ADC had the highest AUC (0.791) in differentiating intra-
hepatica mass-forming cholangiocarcinoma from hepatocellular carcinoma, with 
sensitivity and specificity of 69.7% and 77.6%, respectively [94]. Differentiation 
of benign from malignant cervix tumors was possible by evaluating histograms of 
ADC distributions [84,95]: a significant difference was found between squamous 
cell carcinomas and adenocarcinomas in terms of skewness that supposedly reflects 
a more heterogeneous architecture of adenocarcinomas. The skewness and kurtosis 
of ADC histograms predicted response to angiogenic therapy in recurrent high-
grade gliomas showing that patients with increased skewness had a shorter 
progression-free survival compared with patients with stable or decreased skewness 
[96]. Identification of early response in patients with newly diagnosed or recurrent 
ovarian cancer was possible demonstrating significantly decreased ADCskewness and 
ADCkurtosis after a third cycle of therapy [97]. Finally, metrics derived from ADC 
histograms have been also correlated to several immunohistochemical features of 
solid tumors. For example, Meyer et al [98] reported that the ADCmax correlated 
with p53 expression (p = -0.446, p = 0.009) and ADCmode correlated with Her2-
expression (p = -0.354, p = 0.047) in head and neck squamous cell carcinomas. 
Moreover, 25th percentile, 90th percentile and ADCentropy correlated with Hif1-alpha 
(p = -0.423, p = 0.05, p = -0.494, p = 0.019, p = 0.479, p = 0.024, respectively). 
ADCkurtosis correlated with P53 expression (p = -0.466, p = 0.029). Another study 
[99] revealed a strong correlation between EGFR expression and ADCmax (p=0.72, 
P=0.02), an inverse correlation between ADCkurtosis and ADCskewness with p53 
expression (p=-0.64, P=0.03 and p=-0.81, P=0.002, respectively) and between 
ADCmedian and ADCmode with Ki67 (p=-0.62, P=0.04 and p=-0.65, P=0.03, 
respectively) in rectal cancer. Moreover, PD1-positive tumors showed statistically 
significant lower ADCmax values in comparison to PD1-negative tumors, 1.93 ± 
0.36 vs 2.32 ± 0.47×10-3mm2/s, p=0.04.  
23 
 
 
 
2. Aims of the study 
 
To evaluate MR-derived whole-tumor histogram analysis parameters in predicting 
aggressiveness of PDACs and neuroendocrine neoplasms panNENs, by correlating 
them to pathological features.  
24 
 
 
 
3. Materials and methods 
 
a) Patient cohort 
Between January 2013 and December 2017, 355 consecutive patients with PDAC 
or panNENs who underwent MR within 1 month before surgery at our institution 
were identified through a review of our pathologic and radiologic databases. 
Inclusion criteria were: (a) optimal diagnostic quality MR images without any 
severe motion artifact; (b) unifocal disease; (c) patients who did not undergo local 
or systemic treatments before surgery, except for somatostatin analogues in 
hyperfunctioning panNENs; (d) patients who underwent demolitive surgery with 
standard or extended lymphadenectomy. Exclusion criteria were: (a) suboptimal 
diagnostic quality MR images with motion artifacts; (b) multifocal or diffuse 
disease with difficult delineation of tumor margins; (c) local or systemic treatments 
before surgery; (e) minimally invasive surgery without standard lymphadenectomy. 
 
b) Pathological analysis 
For every patient, an experienced pathologist (S.G., with 15 years of experience in 
pancreatic diseases) reviewed the histological reports and the resection specimens 
and recorded the following features: tumor size; grade, according to the 2010 WHO 
classification [20]; absence (-) or the presence (+) of vascular infiltration (V), nodal 
metastases (N) and liver metastases (M). Vascular infiltration was assessed during 
surgery. Final diagnosis of liver metastases was obtained with percutaneous US-
guided FNA or at pathological analysis of resection specimens. 
 
c) MR Imaging: technical parameters and examination protocol 
All examinations were performed with a 1.5 T unit (Aera, Siemens Medical 
Solutions, Erlangen, Germany) with a multi-channel phased-array torso coil. 
Baseline MR sequences included breath-hold axial, coronal, sagittal and para-
coronal T2-weighted (T2w) imaging with a half-Fourier acquisition single-shot 
turbo spin-echo (HASTE) sequence, axial T2w fat-suppressed (FS) sequence, axial 
T1-weighted (T1w) Dixon sequence; diffusion-weighted imaging using a free-
breathing single-shot echo-planar imaging pulse sequence with b values of 50, 400, 
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and 800 sec/mm2, with automatic reconstruction of ADC maps; and a breath-hold 
T1w FS gradient-echo sequence (volume-interpolated breath-hold examination, 
VIBE). Dynamic MR images were obtained by using the FS three-dimensional 
gradient-echo sequence before and after administration of gadopentate 
dimeglumine (Multihance; Bracco, Milan, Italy) at a dose of 0.1 mmol per kilogram 
of body weight at an injection rate of 2 mL/sec. The timing for post-contrast 
imaging was determined by fixed delays (30-45 seconds after the start of contrast 
medium administration for arterial phase imaging; 60-70 seconds  
for portal phase imaging; and >180 seconds for delayed phase imaging). The 
acquisition of three-dimensional gradient-echo data for each phase was acquired 
during breath hold at end expiration. Detailed MR imaging parameters are 
summarized in table 1. 
 
26 
 
 
 
 
 
  
Table 1 MR imaging acquisition protocol 
Sequence and 
imaging plane 
TR/TE 
(msec) 
Field of 
View 
(mm) 
Matrix Flip Angle (degrees) 
Thickness 
(mm) 
T2w      
Axial ∞/90 400-450 512x384 180 6 
Coronal ∞/90 400-450 364x384 180 6 
Sagittal ∞/90 390-400 253x512 180 4 
Paracoronal ∞/90 400-430 253x512 180 4 
DW axial 6000/59 400-440 192x144 90 6-6.5 
T2w FS axial 2900/82 400-460 384x174 160 6-6.5 
T1w chemical-shift 
axial 
6.69/2.39-
4.77 400-430 320x173 10 3-3.5 
T1w FS      
Axial 6.1/2.4 400-480 320x256 10 3-3.5 
Coronal 6.1/2.4 400-450 187x256 10 3 
2D MRCP ∞/746 300 384x384 180 70 
 
Legend: TR, repetition time; TE, time of echo; T2w, T2-weighted; DW, diffusion-
weighted; FS, fat suppressed; T1w, T1-weighted; MRCP, magnetic resonance 
cholangiopancreatography. 
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d) Image analysis 
 
All MR data were digitally transferred from a picture archiving and communication 
system workstation to a personal computer. Image analysis was performed by two 
radiologists in consensus (R.D. and N.C., with 10 and 8 years of experience in 
abdominal MR imaging) who were blinded to the pathologic results by using a 
software for medical image processing (MevisLab; Mevis Medical Solutions, 
Bremen, Germany) loaded with an in-house graphical user interface. The axial MR 
sequence in whom the tumor showed its highest conspicuity was chosen for tumor 
segmentation; ROIs were manually drawn in every contiguous slice containing the 
tumor and then copied onto the other MR sequences. Tumor boundaries were 
defined by correlating all MR images, including high b-value DW images. The data 
acquired from each slice were then automatically summated to derive volumes of 
interest (VOIs). Each tumor segmentation took a median of 8 minutes (range, 5-20 
minutes). Histograms were obtained from axial Dixon-derived in phase T1w, T1w 
FS, T2w, T2w FS, and postcontrast images, as well as the ADC maps. Histogram 
analysis of the distribution of intensity and ADC values was performed by using 
mathematical analytical software (Matlab 2009a; Mathworks, Natick, USA). 
Several quantitative parameters were derived: skewness, mean, kurtosis, variance, 
entropy, standard deviation (SD), minimum, maximum, median, 25th percentile, 
75th percentile, 95th percentile, interquartile range (IQR) and uniformity. As 
previously reported by Sidhu et al [100], absolute T2 and T1 weighted signal 
intensities are not comparable across patients without standardization, unlike ADC 
maps; therefore, T1 and T2 mean, variance, SD, minimum, maximum, median, 
percentiles and IQR were not analyzed further.  
 
e) Statistical analysis 
All statistical analyses were performed with commercially available software 
(SPSS 23; SPSS, Chicago, USA; and MedCalc 17.9; MedCalc Software, 
Mariakerke, Belgium). For the purpose of statistical analysis, basing on their similar 
biological behavior [30,101], well- and moderately differentiated PDACs as well 
as G2 and G3 panNENs were grouped and considered together. 
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Histogram-derived parameters were then compared among pathological features of 
the tumors (i.e., low vs high grade; V- vs V+; N- vs N+; and M- vs M+) using 
Mann-Whitney U test. 
Receiver operating characteristic (ROC) curves were constructed to determine the 
optimum threshold for each histogram parameter to identify poorly 
differentiate/G2-3, V+, N+ and M+ tumors, and optimal cutoff points were 
individuated according to the Youden’s index, with calculation of sensitivity and 
specificity. Pairwise comparison of ROC curves was performed by calculating the 
standard error of the area under the curve (AUC) and the difference between the 
AUCs, according to the method described by Delong et al [102]. 
For all statistical analyses, a p value less than .05 was considered to indicate a 
significance difference. 
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4. Results 
 
a) Study population 
One hundred-eighty-six patients were excluded from this study for the following 
reasons: suboptimal image quality of MR examinations, with severe motion 
artifacts from limited breath holding (n= 125); enucleation of a tumor smaller than 
1 cm (n= 11; all insulinomas); and previous therapy (n= 50). Finally, 169 patients 
(mean age, 60.5 years; age range, 24-81 years) were included in this study. There 
were 127 PDACs (mean age, 66.2 years; age range, 45-81 years) and 42 panNENs 
(mean age, 54.9 years; age range, 24-75 years). 
 
b) Pathological analysis 
All primary tumors were successfully resected (127 pancreaticoduodenectomies; 
40 distal pancreatectomies; 2 total pancreatectomies). Details are presented in table 
2. 
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Table 2 Clinicopathological data of the study population 
 
Feature PDACs panNENs Total 
Number of cases 127 (75.1%) 42 (24.9%) 169 (100%) 
Age (mean, range) 66.2 (45-81) 54.9 (24-75) 60.5 (24-81) 
Sex 
Male 
Female 
 
77 (60.6%) 
50 (39.4%) 
 
23 (54.8%) 
19 (45.2%) 
 
100 (59.2%) 
69 (40.8%) 
Grade 
WD/G1 
MD/G2 
PD/G3 
 
2 (1.6%) 
114 (89.8%) 
11 (8.6%) 
 
18 (42.8%) 
21 (50%) 
3 (7.2%) 
 
20 (11.8%) 
135 (79.9%) 
14 (8.3%) 
Location 
Head 
Body 
Tail 
 
109 (85.8%) 
15 (11.8%) 
3 (2.4%) 
 
18 (42.9%) 
15 (35.7%) 
9 (21.4%) 
 
127 (75.1%) 
30 (%) 
12 (%) 
Surgery 
PaD 
DP 
TP 
 
109 (85.8%) 
16 (12.6%) 
2 (1.6%) 
 
18 (42.9%) 
24 (57.1%) 
0 (0%) 
 
127 (75.1%) 
40 (23.7%) 
2 (1.2%) 
Vascular infiltration 
No 
Yes 
 
99 (77.9%) 
28 (22.1%) 
 
35 (83.3%) 
7 (16.7%) 
 
134 (79.3%) 
35 (20.7%) 
Nodal metastases 
No 
Yes 
 
25 (19.7%) 
102 (80.3%) 
 
19 (45.2%) 
23 (54.8%) 
 
44 (26%) 
125 (74%) 
Liver metastases 
No 
Yes 
 
127 (100%) 
0 (0%) 
 
35 (83.3%) 
7 (16.7%) 
 
162 (95.9%) 
7 (4.1%) 
 
Data are expressed as number of cases (%), unless otherwise indicated. Legend: 
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; 
PaD, pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total 
pancreatectomy. 
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PDACs 
At pathological analysis there were 2 well differentiated (WD) PDACs (1.6%), 114 
moderately differentiated (MD) PDACs (89.8%) and 11 poorly differentiated (PD) 
PDACs (8.6%). Most PDACs were located in the pancreatic head (N=109, 85.8%), 
15 were located in the pancreatic body (11.8%) and 3 (2.4%) in the pancreatic tail. 
Vascular involvement was identified at pre-operative MR in 28 cases (22.1%) and 
confirmed during surgery in all cases. Nodal metastases were diagnosed in 102 
cases (80.3%). None of the patients with PDAC had liver metastases. Mean size of 
PDACs was 27.8 mm (7-60 mm). 
 
panNENs 
Regarding panNENs, there were 18 G1 tumors (42.8%), 21 G2 tumors (50%) and 
3 G3 tumors (7.2%). All panNENs had well differentiated morphology at 
pathological analysis. Eighteen panNENs were located in the pancreatic head 
(42.9%), 15 were located in the pancreatic body (35.7%) and 9 (21.4%) in the 
pancreatic tail. Vascular involvement was identified at pre-operative MR in 7 cases 
(16.7%) and confirmed during surgery in all cases. Nodal metastases were 
diagnosed in 19 cases (45.2%). Seven patients with panNEN had liver metastases 
(16.7%); all patients with liver metastases were correctly identified by MR. The 
pathological confirmation of liver metastases was obtained after surgical resection 
in 4 cases and with pre-operative FNA in 3 cases. Mean size of panNENs was 32.6 
mm (11-105 mm). 
 
c) Histogram analysis 
The results of the Mann-Whitney’s U test for the comparison between histogram-
derived parameters and pathological features are presented in tables 3-8. 
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PDACs 
No significant differences were among histogram-derived parameters of PDACs of 
different grade. The results of ROC analysis for significantly different histogram-
derived parameters in PDACs are presented in tables 3 and 4. 
T2entropy, T2fsentropy, and ADCentropy were significantly higher in V+ PDACs 
compared with V- tumors. At ROC analysis, there were no significant differences 
between the AUCs of T2entropy, T2fsentropy and ADCentropy for the identification of 
PDACs with vascular infiltration (figures 1 and 2), even though ADCentropy reported 
the highest AUC (.641); at a cut-off of 6.65, this parameter identified V+ PDACs 
with 92.9% specificity and 35.3% specificity. 
ADCskewness was significantly higher in N+ PDACs compared with N- tumors 
(AUC=.642; figure 3). At a given cut-off value of 0.52, ADCskewness identified N+ 
PDACs with 53.9% sensitivity and 72% specificity. 
No significant differences between groups were found for other histogram-derived 
parameters (p >.05). 
Table 3 Comparison between histogram-derived parameters and presence of 
vascular involvement in PDACs. 
 
Vascular involvement T2fsentropy T2entropy ADCentropy 
V-a 6.67 ± 0.7 7.47 ± 0.64 6.88 ± 0.89 
V+ a 7.03 ± 0.61 7.58 ± 0.39 7.46 ± 0.89 
P .044 .048 .022 
AUC .626 .623 .641 
 
aData are mean ± standard deviation. 
Table 4 Comparison between histogram-derived parameters and presence of 
nodal metastases in PDACs. 
 
Nodal metastases ADCskewness 
N-a 0.21 ± 0.57 
N+a 0.54 ± 0.69 
P .027 
AUC .642 
 
aData are mean ± standard deviation. 
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Figure 1. Findings in a 62-year-old man with a ductal adenocarcinoma of the 
pancreatic head. (a) On axial portal phase T1-weighted image the tumor is 
homogeneously hypointense; infiltration of the superior mesenteric vein can be 
seen (arrow). (d) Whole-tumor histogram analysis of ADC values provided high 
entropy value (7.50). 
 
 
Figure 2. Comparison of ROC curves of ADCentropy, T2entropy and T2fsentropy for the 
identification of V+ PDACs. 
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Figure 3. ROC curve of ADCskewness for identification of N+ PDACs. 
 
 
PanNENs 
T2skewness, ADCkurtosis, and ADCentropy were significantly higher in G2-3 tumors 
compared with G1 tumors, as well as in V+ compared with V- tumors; ADCuniformity 
was significantly lower in G2-3 tumors compared with G1 tumors and in V+ 
compared with V- panNENs (figures 4 and 5). 
ADCkurtosis and ADCentropy were significantly higher in N+ panNENs compared with 
N- tumors; ADCmedian and ADC75 were significantly lower in N+ compared with N- 
panNENs. Finally, ADCkurtosis and ADCmax were significantly higher in M+ 
compared with M- tumors (figure 6). No significant differences between groups 
were found for other histogram-derived parameters (p >.05). 
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Figure 4 (a-d). Findings in a 54-year-old man with a G2 neuroendocrine tumor of 
the pancreatic head. (a) Resection specimen (pancreaticoduodenectomy; transverse 
cut): at histopathologic examination the tumor shown to a be a G2 (Ki67=5%), N1 
panNEN. (b) On axial T2-weighted image the tumor is inhomogeneously 
hyperintense; upstream chronic obstructive pancreatitis can be seen (arrow). (c) 
Infiltration of the superior mesenteric vein can be seen on postcontrast portal phase 
image (arrow). (d) Whole-tumor histogram analysis of ADC values provided high 
entropy and kurtosis values (9.01 and 4.68). 
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Figure 5 (a-d). Findings in a 55-year-old man with a pancreatic head 
neuroendocrine tumor associated with vascular infiltration. (a) On postcontrast 
arterial phase MR image the tumor is hypointense and present ill-defined margins 
(arrow). (b) Infiltration of the superior mesenteric vein can be seen on postcontrast 
portal phase image (arrow). (c) Histogram of whole-lesion ADC values shows a 
sharp peak, consistent with high kurtosis (5.56); entropy was 8.91. (d) 
Histopathologic examination shown that the tumor was a G2 (Ki67=15%), N1 and 
confirmed tumor infiltration of the superior mesenteric vein (Hematoxylin-eosin 
stain; original magnification, ×100). 
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Figure 6 (a-d). Findings in a 47-year-old man with a pancreatic head 
neuroendocrine tumor associated with liver metastases. (a) Resection specimen 
(pancreaticoduodenectomy; transverse cut); the tumor shown to be a G2 
(Ki67=5%), N1 panNEN. (b) On postcontrast arterial phase MR image the tumor 
shows inhomogeneous enhancement (arrow). (c) Liver metastases can be seen on 
DW image (arrows). (d) Histogram of whole-lesion ADC values demonstrated a 
sharp peak, indicating high kurtosis (4.01); entropy was 9.44. 
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The results of ROC analysis for significantly different histogram-derived 
parameters are presented in tables 5-8. At ROC analysis, ADCentropy had the highest 
AUC for the identification of G2-3 tumors (.757); sensitivity and specificity for the 
identification of G2-3 panNENs were 83.3% (95% CI: 61.2-94.5) and 61.1% (95% 
CI: 36.1-81.7). ADCkurtosis showed the highest AUC under the ROC curve for 
identifying V+, N+ and M+ panNENs (.820, .709, and .820, respectively; figures 
5, 6 and 7); sensitivity and specificity were: 85.7/74.3% (95% CI: 42-99.2 /56.4-
86.9); 36.8/96.5% (95% CI: 17.2-61.4 /76-99.8); and 100/62.8% (95% CI: 56.1-
100/44.9-78.1). 
Pairwise comparison did not show any significant difference between ROC curves 
(figure 7). 
 
 
Table 5 Comparison between histogram-derived parameters and tumor grade 
in panNENs. 
 
Grade T2skewness ADCkurtosis ADCentropy ADCuniformity 
G1a 0.37 ± 0.78 2.95 ± 1.35 5.95 ± 2.34 0.015 ± 0.015 
G2-3a 0.9 ± 0.85 5.95 ± 7.95 7.95 ± 1.55 0.006 ± 0.008 
P .040 .015 .005 .014 
AUC .688 .720 .757 .722 
 
aData are mean ± standard deviation. 
 
Table 6 Comparison between histogram-derived parameters and presence of 
vascular involvement in panNENs. 
 
Vascular 
involvement T2skewness ADCkurtosis ADCentropy ADCuniformity 
V-a 1.37 ± 1.06 3.54 ± 2.37 6.77 ± 2.18 0.011 ± 0.013 
V+ a 0.54 ± 0.75 5.58 ± 2.95 8.70 ± 1.02 0.003 ± 0.002 
P .045 .008 .028 .041 
AUC .688 .820 .763 .747 
 
aData are mean ± standard deviation. 
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Table 7 Comparison between histogram-derived parameters and presence of nodal 
metastases in panNENs. 
 
Nodal 
metastases ADCkurtosis ADCentropy ADCmedian ADC75 
N-a 3.08 ± 1.22 6.31 ± 2.38 1273.5 ± 345.91 1552.81 ± 452.18 
N+a 4.84 ± 3.36 8.04 ± 1.35 1079.45 ± 217.40 1302.59 ± 218.31 
P .021 .027 .042 0.24 
AUC .709 .700 .684 .705 
 
aData are mean ± standard deviation. 
Table 8 Comparison between histogram-derived parameters and presence of liver 
metastases. 
 
Liver metastases ADCkurtosis ADCmax 
M-a 3.26 ± 1.27 2235.63 ± 622.5 
M+ a 6.94 ± 4.75 2832.71 ± 533.01 
P .008 .019 
AUC .820 .784 
 
aData are mean ± standard deviation. 
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Figure 7. Comparison of histogram-derived ROC curves. (a) ROC curves of ADC 
entropy, kurtosis, uniformity and T2skewness for the identification of G2-3 panNENs. 
(b) ROC curves of ADC entropy, kurtosis, uniformity and T2skewness for the 
identification of V+ panNENs. (c) ROC curves of ADC entropy, kurtosis, median 
and 75th percentile for the identification of N+ panNENs. (d) ROC curves of ADC 
kurtosis and maximum value for the identification of M+ tumors. 
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5. Discussion 
 
This study evaluated the diagnostic accuracy of histogram-derived MR parameters 
in predicting grade and aggressiveness in PDACs and panNENs. Previous work 
[103] suggested that histogram analysis of ADC maps can be useful in 
differentiating histologic grades of panNENs. Our results confirm these findings: 
in the present study, ADCentropy was the parameter with the highest accuracy in 
identifying high grade panNENs (AUC=.757), with 83.3% sensitivity. ADCentropy 
was also the parameter with the highest accuracy in identifying PDACs with 
vascular infiltration (AUC=.641, specificity 92.2%). ADCkurtosis was found to be the 
parameter with the highest diagnostic accuracy (AUC= .820, .709, and .820, 
respectively) for the identification of panNENs with vascular infiltration, nodal and 
hepatic metastases: sensitivity and specificity of this parameter were 85.7/74.3%, 
36.8/96.5%, and 100/62.8%, respectively. Finally, ADCskewness was significantly 
higher in PDACs with nodal metastases compared with N- tumors (p=.027; 
AUC=.642), with a reported specificity of 72%. 
Histogram analysis of ADC data can interrogate the biologic heterogeneity of 
tumors by classifying domains of different diffusivity, which may have prognostic 
and predictive implications [74]. Two quantities calculated by using this histogram 
analysis are uniformity and entropy. These parameters characterize the uniformity 
and the irregularity of intra-tumor voxel distribution [104,105]. When histogram 
analysis is performed on solid tumors, entropy and uniformity therefore reflect and 
quantify intratumoral heterogeneity. Kurtosis is a measure of the magnitude of pixel 
distribution, representing how peaked a histogram is; on the ADC histogram 
distribution, kurtosis represents the position of peak height that indicate the ADC 
value of the maximum frequency [85]. Such metrics demonstrated to be reliable 
markers of tumor heterogeneity, with correlation to the structural, physiological, 
molecular and metabolic changes occurring upon tumor progression and during 
therapy [85]. Higher kurtosis and entropy, as well as lower uniformity, are thought 
to represent microstructural and functional heterogeneity and are associated with 
poorer prognosis [85]. Our results confirm this hypothesis, as both ADCentropy and 
ADCkurtosis were significantly higher in panNENs with higher malignancy compared 
42 
 
 
 
to G1, V-, N- and M- tumors (all p <.05); ADCentropy was also significantly higher 
in PDACs infiltrating peri-pancreatic vessels compared to V- tumors. 
Skewness is another metric of heterogeneity, representing a measure of asymmetry 
of the probability distribution. In the present study, ADCskewness was found to be 
only significant predictor of nodal metastases in PDACs: N+ PDACs had 
significantly higher ADCskewness compared to N- PDACs. 
There are very few studies on MR histogram analysis of pancreatic tumors. 
ADC histograms may be helpful in differentiating between pancreatic cancer and 
focal pancreatitis as well as between PDACs and panNENs. Ma et al [106] found 
that 50th and 100th ADC percentiles can reflect tissue heterogeneity and help 
differentiate normal pancreas from focal pancreatitis and PDAC. Shindo et al [107] 
reported that ADC histogram analysis can help differentiate PDACs from 
panNENs: the mean ADC200 and ADC400 were significantly higher in panNENs 
than in PDACs (P = 0.001 and P = 0.019, respectively); PDACs showed significantly 
higher skewness and kurtosis on ADC400 (P = 0.007 and P = 0.001, respectively) 
and ADC800 (P = 0.001 and P = 0.001, respectively). With all b-value combinations, 
the entropy of ADC values was significantly higher in PDACs (P < 0.001 for 
ADC200; P = 0.001 for ADC400; P < 0.001 for ADC800), and showed the highest 
area under the ROC curve for diagnosing carcinomas (0.77 for ADC200, 0.76 for 
ADC400, and 0.78 for ADC800). 
Histogram-derived parameters may also be helpful in identifying pancreatic tumors 
with higher malignant potential. Pereira et al [103] found that histographic analysis 
of ADC maps on the basis of the entire tumor volume can be useful in 
differentiating histologic grades of panNENs: the mean, 75th, 90th, and 95th 
percentiles were significantly higher in G1 tumors compared to G2 and to G3 
tumors; ADC skewness and kurtosis were significantly different between G1 and 
G3 tumors. Hoffman et al [108] reported that ADCentropy may serve as a biomarker 
for identifying the malignant potential of intraductal papillary mucinous neoplasms 
(IPMNs). In this study, ADC histogram metrics demonstrating significant 
differences between benign and malignant IPMNs were: entropy (5.1 ± 0.2 vs. 5.4 
± 0.2; p = 0.01, AUC = 86%); mean of the bottom 10th percentile (2.2 ± 0.4 vs. 1.6 
± 0.7; p = 0.03; AUC = 81%); and mean of the 10-25th percentile (2.8 ± 0.4 vs. 2.3 
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± 0.6; p = 0.04; AUC = 79%). For ADCentropy, an optimal threshold of >5.3 achieved 
a sensitivity of 100%, a specificity of 70%, and an accuracy of 83% for predicting 
malignancy in pancreatic IPMNs. 
Considering our results and the aforementioned studies, imaging of tumor 
heterogeneity may provide a non-invasive assessment of aggressiveness and 
prognosis in pancreatic tumors. 
The retrospective nature of this study was a limitation. Other limitations are the 
small amount of WD and PD PDACs and G3 panNENs as well as the small number 
of panNENs with vascular infiltration and liver metastases. Moreover,  
the inclusion criteria of this study may have been resulted in a selection bias, as 
unresectable PDACs were excluded; histogram-derived distributions in this group 
of tumors remains to be evaluated. 
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6. Conclusions 
 
Whole-tumors histogram analysis of ADC values may represent a valuable non-
invasive tool in predicting the aggressiveness of PDACs and panNENs. Our results 
indicate that histogram metrics related to intra-tumor heterogeneity, as ADCentropy, 
ADCkurtosis and ADCskewness are the most accurate parameters for the identification 
of PDACs and panNENs with higher biological aggressiveness. Further and larger 
studies are needed to incorporate the results of the histogram analysis within 
decision support models and to mine these data to detect possible correlations with 
genomic patterns. 
  
45 
 
 
 
7. References 
 
1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer 
mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–1656. 
2. Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal 
adenocarcinoma. Semin Oncol. 2015;42:8–18. 
3. Larsson SC, Wolk A. Red and processed meat consumption and risk of 
pancreatic cancer: meta-analysis of prospective studies. Br J Cancer. 
2012;106:603–607. 
4. Ojajarvi IA, Partanen TJ, Ahlbom A, et al. Occupational exposures and 
pancreatic cancer: a meta-analysis. Occup Environ Med. 2000; 57:316–324. 
5. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann 
Oncol. 2015;26: v56–v68. 
6. Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy 
vs Chemotherapy on Survival in Patients With Locally Advanced 
Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or 
Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 
2016;315(17):1844-1853. 
7. Shinchi H, Takao S, Noma H, et al. Length and quality of survival after 
external-beam radiotherapy with concurrent continuous 5-fluorouracil 
infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol 
Phys. 2002;53:146–150. 
8. Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, 
including meta-analyses, on the management of locally advanced pancreatic 
cancer using radiation/combined modality therapy. Br J Cancer. 2007; 
96:1183–1190. 
9. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing 
intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and 
intermittent cisplatin) followed by maintenance gemcitabine with 
gemcitabine alone for locally advanced unresectable pancreatic cancer. 
46 
 
 
 
Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 
2008;19(9):1592-1599. 
10. Loehrer PJ Sr, Feng Y, Cardenes H, et al.  Gemcitabine alone versus 
gemcitabine plus radiotherapy in patients with locally advanced pancreatic 
cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 
2011;29:4105–4112. 
11. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or 
capecitabine- based chemoradiotherapy for locally advanced pancreatic 
cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 
2013;14:317–326. 
12. NCCN guidelines for Pancreatic Adenocarcinoma, v. 2.2018. 
13. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic 
cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 
2013;369(18):1691-1703. 
14. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine 
for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. 
15. Rishi A, Goggins M, Wood LD, Hruban RH. Pathological and molecular 
evaluation of pancreatic neoplasms. Semin Oncol. 2015;42:28–39. 
16. Wisnoski NC, Townsend CM Jr, Nealon WH, Freeman JL, Riall TS. 672 
patients with acinar cell carcinoma of the pancreas: a population-based 
comparison to pancreatic adenocarcinoma. Surgery. 2008;144:141–148. 
17. Esposito I, Konukiewitz B, Schlitter AM, Klöppel G. Pathology of 
pancreatic ductal adenocarcinoma: facts, challenges and future 
developments. World J Gastroenterol. 2014; 20:13833–13841. 
18. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic 
cancer progression. Oncogene. 2013;32(45):5253-5260. 
19. Waddell N, Pajic M, Patch AM,  et al. Whole genomes redefine the 
mutational landscape of pancreatic cancer. Nature. 2015;518:495–501. 
20. Bosman FT, Carneiro F, Hruban RH, Theise N, editors. WHO 
Classification of Tumors of the Digestive System. Lyon: IARC Press; 2010. 
pp. 13–14. 
47 
 
 
 
21. Milione M, Maisonneuve P, Spada F et al. The clinicopathologic 
heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: 
Morphological differentiation and proliferation identify different prognostic 
categories. Neuroendocrinology 2017;104:85–93. 
22. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA 
Cancer J Clin.  2018 Oct 8 [Epub ahead of print]. 
23. Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning 
insulinoma - incidence, recurrence, and long-term survival of patients: a 60-
year study. Mayo Clin Proc. 1991;66:711-719. 
24. Whipple AO. Islet cell tumours of pancreas. Can Med Assoc J. 
1952;66:334-342. 
25. Jensen RT. Gastrinomas: advances in diagnosis and management. 
Neuroendocrinology. 2004;80:23-27. 
26. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory 
watery diarrhea and hypokalemia. Am J Med. 1958;25:374-380. 
27. van Beek AP, de Haas ER, van Vloten WA, Lips CJ, Roijers JF, Canninga-
van Dijk MR. The glucagonoma syndrome and necrolytic migratory 
erythema: a clinical review. Eur J Endocrinol. 2004;151:531-537. 
28. Oberg K. Management of functional neuroendocrine tumors of the 
pancreas. Gland Surg. 2018;7:20-27. 
29. Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines 
Update for the Management of Patients with Functional 
Pancreatic Neuroendocrine Tumors and Non-Functional 
Pancreatic Neuroendocrine Tumors. Neuroendocrinology 
2016;103(2):153-171. 
30. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic 
neuroendocrine tumors (PNETs): incidence, prognosis and recent trend 
toward improved survival. Ann Oncol. 2008;19:1727-1733. 
31. Gorelik M, Ahmad M, Grossman D, Grossman M, Cooperman AM. 
Nonfunctioning incidental pancreatic neuroendocrine tumors: who, when, 
and how to treat? Surg Clin North Am. 2018;98:157-167. 
48 
 
 
 
32. Yao JC, Hassan M, Phan A, et al. One hundred years after ‘carcinoid’: 
epidemiology of and prognostic factors for neuroendocrine tumors in 
35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. 
33. Cheslyn-Curtis S, Sitaram V, Williamson RC. Management of non-
functioning neuroendocrine tumours of the pancreas. Br J Surg 
1993;80:625–627.  
34. Madura JA, Cummings OW, Wiebke EA, et al: Nonfunctioning islet cell 
tumors of the pancreas: a difficult diagnosis but one worth the effort. Am 
Surg 1997;63:573–577. 
35. Matthews BD, Heniford BT, Reardon PR, et al: Surgical experience with 
nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 2000; 66: 
1116–1122. 
36. White TJ, Edney JA, Thompson JS, et al: Is there a prognostic difference 
between functional and nonfunctional islet cell tumors? Am J Surg 1994; 
168: 627–629. 
37. Chu QD, Hill HC, Douglass HO Jr, et al: Predictive factors associated with 
long-term survival in patients with neuroendocrine tumors of the pancreas. 
Ann Surg Oncol 2002; 9:855–862. 
38. Schurr PG, Strate T, Rese K, et al: Aggressive surgery improves long-term 
survival in neuroendocrine pancreatic tumors: an institutional experience. 
Ann Surg 2007;245:273– 281. 
39. Bilimoria KY, Talamonti MS, Tomlinson JS, et al: Prognostic score 
predicting survival after resection of pancreatic neuroendocrine tumors: 
analysis of 3,851 patients. Ann Surg 2008;247:490–500. 
40. Bettini R, Boninsegna L, Mantovani W, et al: Prognostic factors at diagnosis 
and value of WHO classification in a mono-institutional series of 180 non-
functioning pancreatic endocrine tumours. Ann Oncol 2008;19:903– 908. 
41. Scarpa A, Mantovani W, Capelli P, et al: Pancreatic endocrine tumors: 
improved TNM staging and histopathological grading permit a clinically 
efficient prognostic stratification of patients. Mod Pathol 2010;23:824– 
833. 
49 
 
 
 
42. Triponez F, Dosseh D, Goudet P, et al: Epidemiology data on 108 MEN-1 
patients from the GTE with isolated nonfunctioning tumors of the pancreas. 
Ann Surg 2006;243: 265–272. 
43. Hammel PR, Vilgrain V, Terris B, et al: Pancreatic involvement in von 
Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de 
von Hippel-Lindau. Gastroenterology. 2000;119:1087–1095. 
44. Blansfield JA, Choyke L, Morita SY, et al: Clinical, genetic and 
radiographic analysis of 108 patients with von Hippel-Lindau disease 
(VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). 
Surgery. 2007;142:814–818. 
45. Cives M, Strosberg J. The expanding role of somatostatin analogs in 
gastroenteropancreatic and lung neuroendocrine tumors. Drugs. 2015;75: 
847-858. 
46. Jiao Y, Shi C, Edil BH, et al. DAXX/ ATRX, MEN1, and mTOR pathway 
genes are frequently altered in pancreatic neuroendocrine tumors. Science. 
2011;331:1199-1203. 
47. Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of 
pancreatic neuroendocrine tumours. Nature. 2017;543:65-71. 
48. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial 
growth factor in digestive neuro-endocrine tumours. Histopathology. 
1998;32:133-138. 
49. Oberg K, Casanovas O, Castano JP, et al. Molecular pathogenesis of neuro- 
endocrine tumors: implications for current and future therapeutic 
approaches. Clin Cancer Res. 2013;19:2842-2849. 
50. Asa SL. Pancreatic endocrine tumors. Mod Pathol. 2011;24(2):S66-S77. 
51. Hill JS, McPhee JT, McDade TP, et al: Pancreatic neuroendocrine tumors: 
the impact of surgical resection on survival. Cancer 2009; 115:741–751. 
52. La Rosa S, Klersy C, Uccella S, et al: Improved histologic and 
clinicopathologic criteria for prognostic evaluation of pancreatic endocrine 
tumors. Hum Pathol 2009;40:30– 40. 
50 
 
 
 
53. Bettini R, Partelli S, Boninsegna L, et al: Tumor size correlates with 
malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 
2011;150:75–82. 
54. Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. 
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting 
somatostatin analogue. N Engl J Med. 1986;315:663-666. 
55. Rinke A, Muller HH, Schade-Brittinger C, et al. PROMID Study Group. 
Placebo-controlled, double-blind, prospective, randomized study on the 
effect of octreotide LAR in the control of tumor growth in patients with 
metastatic neuroendocrine midgut tumors: a report from the PROMID 
Study Group. J Clin Oncol. 2009;27:4656-4663. 
56. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic 
enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224-233. 
57. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic 
neuroendocrine tumors. N Engl J Med. 115. 2011;364:514-523. 
58. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of 
pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513. 
59. D’Onofrio M, Capelli P, Pederzoli P, editors. Imaging and pathology of 
pancreatic neoplasms. Milan: Springer-Verlag; 2015. pp. 1-102. 
60. D’Onofrio M, Capelli P, Pederzoli P, editors. Imaging and pathology of 
pancreatic neoplasms. Milan: Springer-Verlag; 2015. pp. 103-194. 
61. De Robertis R, D’Onofrio M, Zamboni G, et al. Pancreatic neuroendocrine 
neoplasms: clinical value of diffusion-weighted imaging. 
Neuroendocrinology. 2016;103:758-770. 
62. Bakir B, Salmaslioğlu A, Poyanli A, Rozanes I, Acunas B. Diffusion 
weighted MR imaging of pancreatic islet cell tumors. Eur J Radiol. 
2010;74:214–220. 
63. Brenner R, Metens T, Bali M, Demetter P, Matos C. Pancreatic 
neuroendocrine tumor: added value of fusion of T2-weighted imaging and 
high b-value diffusion-weighted imaging for tumor detection. Eur J Radiol. 
2012;81:e746–e749. 
51 
 
 
 
64. Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, et al. Comparison 
of abdominal MRI with diffusion- weighted imaging to 68 Ga-DOTATATE 
PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl 
Med Mol Imaging. 2013;40:897–907. 
65. Wang Y, Chen ZE, Nikolaidis P, et al. Diffusion-weighted magnetic 
resonance imaging of pancreatic adenocarcinomas: association with 
histopathology and tumor grade. J Magn Reson Imaging. 2011;33:136-142. 
66. Muraoka N, Uematsu H, Kimura H, et al. Apparent diffusion coefficient in 
pancreatic cancer: characterization and histopathological correlations. J 
Magn Reson Imaging. 2008;27:1302-1308. 
67. Rosenkrantz AB, Matza BW, Sabach A, Hajdu CH, Hindman N. Pancreatic 
cancer: lack of association between apparent diffusion coefficient values 
and adverse pathological features. Clin Radiol. 2013;68:e191-e197. 
68. Legrand L, Duchatelle V, Molinié V, Boulay-Coletta I, Sibileau E, Zins M. 
Pancreatic adenocarcinoma: MRI conspicuity and pathologic correlations. 
Abdom Imaging. 2015;40:85-94. 
69. Hayano K, Miura F, Amano H, et al. Correlation of apparent diffusion 
coefficient measured by diffusion weighted MRI and clinicopathologic 
features in pancreatic cancer patients. J Hepatobiliary Pancreat Sci. 
2013;20:243-248. 
70. Fukukura Y, Takumi K, Higashi M, et al. Contrast-enhanced CT and 
diffusion weighted MR imaging: performance as a prognostic factor in 
patients with pancreatic ductal adenocarcinoma. Eur J Radiol 2014;83:612-
619. 
71. Lotfalizadeh E, Ronot M, Wagner M, et al. Prediction of pancreatic 
neuroendocrine tumour grade with MR imaging features: added value of 
diffusion-weighted imaging. Eur Radiol. 2017;27(4):1748-1759. 
72. Guo C, Chen X, Xiao W, Wang Q, Sun K, Wang Z (2017) Pancreatic 
neuroendocrine neoplasms at magnetic resonance imaging: Comparison 
between grade 3 and grade 1/2 tumors. Onco Targets Ther 10:1465–1474. 
52 
 
 
 
73. De Robertis R, Cingarlini S, Tinazzi Martini P, et al. Pancreatic 
neuroendocrine neoplasms: Magnetic resonance imaging features according 
to grade and stage. World J Gastroenterol. 2015;23(2):275–285. 
74. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than 
pictures, they are data. Radiology. 2016;278(2):563-577. 
75. Wibmer A, Hricak H, Gondo T, et al. Haralick texture analysis of prostate 
MRI: utility for differentiating non-cancerous prostate from prostate cancer 
and differentiating prostate cancers with different Gleason scores. Eur 
Radiol 2015;25(10):2840–2850. 
76. Coroller TP, Grossmann P, Hou Y, et al. CT based radiomic signature 
predicts distant metastasis in lung adenocarcinoma. Radiother Oncol 
2015;114(3):345–350. 
77. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the 
genetic evolution of pancreatic cancer. Nature 2010; 467(7319):1114–1117. 
78. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and 
branched evolution revealed by multiregion sequencing. N Engl J Med 
2012;366(10):883–892. 
79. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in 
human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad 
Sci U S A 2013;110(10): 4009–4014. 
80. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and 
histological evolution of lung cancers acquiring resistance to EGFR 
inhibitors. Sci Transl Med 2011;3(75):75ra26. 
81. De Sousa E Melo f, Vermeulen L, Fessler E, Medema JP. Cancer 
Heterogeneity – a multifaceted view. EMBO Rep. 2013;14(8):686-695. 
82. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current 
status and future directions. J Magn Reson Imaging. 2002; 16(4):407-422. 
83. Peng SL, Chen CF, Liu HL, et al. Analysis of parametric histogram from 
dynamic contrast-enhanced MRI: application in evaluating brain tumor 
response to radiotherapy. NMR Biomed. 2012; 26:443-450. 
84. Downey K, Riches SF, Morgan VA, et al. Relationship between imaging 
biomarkers of stage I cervical cancer and poor-prognosis histologic 
53 
 
 
 
features: quantitative histogram analysis of diffusion-weighted MR images. 
AJR Am J Roentgenol. 2013;200(2):314-320. 
85. Just N. Histogram analysis of the microvasculature of intracerebral human 
and murine glioma xenografts. Magn Reson Med. 2011;65:778-789. 
86. Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ. Percent change of perfusion 
skewness and kurtosis: a potential imaging biomarker for early treatment 
response in patients with newly diagnosed glioblastomas. Radiology. 
2012;264(3):834-843. 
87. Song YS, Choi SH, Park CK, et al. True progression versus 
pseudoprogression in the treatment of glioblastoma: a  comparison study of 
normalized cerebral blood volume and apparent diffusion coefficient by 
histogram analysis. Korean J Radiol. 2013;14(4):662-672. 
88. Chandarana H, Rosenkrantz AB, Mussi TC, et al. Histogram analysis of 
whole-lesion enhancement in differentiating clear cell from papillary 
subtype of renal cell cancer. Radiology. 2012;265(3):790-798. 
89. Woo S, Cho JY, Kim SY, Kim SH. Histogram analysis of apparent diffusion 
coefficient map of diffusion-weighted MRI in endometrial cancer: a 
preliminary correlation study with histological grade. Acta Radiol. 
2014;55(10):1270-1277. 
90. Chang YC, Huang CS, Liu YJ, Chen JH, Lu YS, Tseng WY. Angiogenic 
response of locally advanced breast cancer to neoadjuvant chemotherapy 
evaluated with parametric histogram from dynamic contrast-enhanced MRI. 
Phys Med Biol. 2004;49(16):3593-602. 
91. Wen Q, Jalilian L, Lupo JM, et al. Comparison of ADC metrics and their 
association with outcome for patients with newly diagnosed glioblastoma 
being treated with radiation therapy, temozolomide, erlotinib and 
bevacizumab. J Neurooncol. 2015 Jan;121(2):331-339. 
92. Foroutan P, Kreahling JM, Morse DL, et al. Diffusion MRI and novel 
texture analysis in osteosarcoma xenotransplants predicts response to anti-
checkpoint therapy. PLoS One. 2013;8(12):e82875. 
54 
 
 
 
93. Tozer DJ, Jäger HR, Danchaivijitr N, et al. Apparent diffusion coefficient 
histograms may predict low-grade glioma subtype. NMR Biomed. 
2007;20(1):49-57. 
94. Zou X, Luo Y, Li Z, et al. Volumetric Apparent Diffusion Coefficient 
Histogram Analysis in Differentiating Intrahepatic Mass-Forming 
Cholangiocarcinoma From Hepatocellular Carcinoma. J Magn Reson 
Imaging. 2018 Sep 12. doi: 10.1002/jmri.26253. [Epub ahead of print]. 
95. Rosenkrantz A. Histogram-based apparent diffusion coefficient analysis: an 
emerging tool for cervical cancer characterization? AJR Am J Roentgenol. 
2013;200(2):311–313. 
96. Nowosielski M, Recheis W, Goebel G, et al. ADC histograms predict 
response to anti-angiogenic therapy in patients with recurrent high-grade 
glioma. Neuroradiology. 2011;53(4):291-302. 
97. Kyriazi S, Collins DJ, Messiou C, et al. Metastatic ovarian and primary 
peritoneal cancer: assessing chemotherapy response with diffusion-
weighted MR imaging--value of histogram analysis of apparent diffusion 
coefficients. Radiology. 2011;261(1):182-192. 
98. Meyer HJ, Leifels L, Hamerla G, Höhn AK, Surov A. ADC-histogram 
analysis in head and neck squamous cell carcinoma. Associations with 
different histopathological features including expression of EGFR, VEGF, 
HIF-1α, Her 2 and p53. A preliminary study. Magn Reson Imaging. 2018 
Dec;54:214-217. 
99. Meyer HJ, Höhn A, Surov A. Histogram analysis of ADC in rectal cancer: 
associations with different histopathological findings including expression 
of EGFR, Hif1-alpha, VEGF, p53, PD1, and KI 67. A preliminary study. 
Oncotarget. 2018;9(26):18510-18517. 
100. Sidhu HS, Benigno S, Ganeshan B, et al. Textural analysis of 
multiparametric MRI detects transition zone prostate cancer. Eur Radiol. 
2017;27(6):2348-2358. 
101. Wasif N, Ko CY, Farrell J, et al. Impact of tumor grade on prognosis 
in pancreatic cancer: should we include grade in AJCC staging? Ann Surg 
Oncol. 2010;17(9):2312-2320. 
55 
 
 
 
102. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas 
under two or more correlated receiver operating characteristic curves: a 
nonparametric approach. Biometrics. 1998;44(3):837-845. 
103. Pereira JA, Rosado E, Bali M, Metens T, Chao SL. Pancreatic 
neuroendocrine tumors: correlation between histogram analysis of apparent 
diffusion coefficient maps and tumor grade. Abdom Imaging 
2015;40(8):3122-3128. 
104. Nguyen HT, Shah ZK, Mortazavi A, et al. Non-invasive 
quantification of tumour heterogeneity in water diffusivity to differentiate 
malignant from benign tissues of urinary bladder: a phase I study. Eur 
Radiol. 2017;27:2146-2152. 
105. Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B. 
Assessment of tumor heterogeneity: an emerging imaging tool for clinical 
practice? Insights Imaging. 2012;3(6):573–589. 
106. Ma X, Zhao X, Ouyang H, Sun F, Zhang H, Zhou C. Quantified 
ADC histogram analysis: a new method for differentiating mass-forming 
focal pancreatitis from pancreatic cancer. Acta Radiol. 2014;55(7):785-792. 
107. Shindo T, Fukukura Y, Umanodan T, et al. Histogram Analysis of 
Apparent Diffusion Coefficient in Differentiating Pancreatic 
Adenocarcinoma and Neuroendocrine Tumor. Medicine (Baltimore). 
2016;95(4):e2574. 
108. Hoffman DH, Ream JM, Hajdu CH, Rosenkrantz AB. Utility of 
whole-lesion ADC histogram metrics for assessing the malignant potential 
of pancreatic intraductal papillary mucinous neoplasms (IPMNs). Abdom 
Radiol (NY). 2017;42(4):1222-1228. 
 
